Matsubara, N. Et Al. 2023. Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA. Clinical cancer research : an official journal of the American Association for Cancer Research , vol.29, no.1 , 92-99.

Matsubara, N., de Bono, J., Olmos, D., Procopio, G., Kawakami, S., ÜRÜN, Y., ... van Alphen, R.(2023). Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA. Clinical cancer research : an official journal of the American Association for Cancer Research , vol.29, no.1, 92-99.

Matsubara, Nobuaki Et Al. "Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA," Clinical cancer research : an official journal of the American Association for Cancer Research , vol.29, no.1, 92-99, 2023

Matsubara, Nobuaki Et Al. "Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA." Clinical cancer research : an official journal of the American Association for Cancer Research , vol.29, no.1, pp.92-99, 2023

Matsubara, N. Et Al. (2023) . "Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA." Clinical cancer research : an official journal of the American Association for Cancer Research , vol.29, no.1, pp.92-99.

@article{article, author={Nobuaki Matsubara Et Al. }, title={Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year=2023, pages={92-99} }